Prof. Xu Hong-xi (Ph.D)

Academic qualifications:

1983: BS. Pharmacology Shanghai University of Traditional Chinese Medicine, PRC
1988: MS Chinese Medicine Shanghai University of Traditional Chinese Medicine, PRC
1994: PhD Pharmaceutical Sciences National Research Institute for Sino-Japanese Traditional Medicines, Toyama Medical and Pharmaceutical University, Japan

Previous academic positions held:

2001-2011: Deputy Director, Hong Kong Jockey Club Institute of Chinese Medicine, Director, CMED laboratory
2000-2001: Board of Director & R&D Director, Shanghai Hutchison Pharmaceuticals Ltd, Shanghai
1999-2001: Deputy General Manager, Healthcare Investment, Hutchison Whampoa (China) Ltd., Hong Kong
1997-2001: Senior Consultant, Hutchison Whampoa (China) Ltd., Hong Kong
1997-2001: Consultant, Chamber of Chinese Herbal Medicines of Canada
1998-1999: Scientific Officer and R&D Manager, Chinese Medicinal Material Research Center, Chinese University of Hong Kong
1996-1998: Senior Research Fellow, Department of Chemistry, Dalhousie University, Halifax, Nova Scotia, Canada
1996-1998: Executive Member (Educational Director), The Chinese Society of Nova Scotia, Nova Scotia, Canada
1994-1996: Research Fellow Department of Chemistry, National University of Singapore, Singapore

Present academic position:

2010-present: Dean & Professor, School of pharmacy, shanghai University of traditional Chinese medicine

Publication records

Five most relevant publications in the recent five years *(* Corresponding Author)*

1. Y. Lu, N.M.Kim, Y.W.Jiang, H.Zhang, D. Zheng, F.X. Zhu, R. Liang, B. Li*, **H .X . Xu ***, Cambogin suppresses dextran sulphate sodium-induced colitis by enhancing Treg cell stability and function. British Journal of Pharmacology, 175: 1085–1099 (2018)
2. L.F.Xu, X.X.Meng, N.H.Xu, W.W.Fu, H.S.Tan, L.Zhang, Q.J.Zhou, J.N.Qian, S.W.Tu, X.T. Li, Y.Z. Lao*, **H .X . Xu** *, Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth, Cell Death & Disease, 9: 262 (2018)
3. Y.Y. Li, Y. Lu, S.W.Wang, Z.J.Han, F.X.Zhu, Y.M.Ni, R.Liang, Y.Zhang, Q.B. Leng, G.Wei, G.C.Shi, R.H.Zhu, D.Li, H.K.Wang, S.G.Zheng, **H.X.Xu**, A.Tsun, B. Li*, USP21 prevents the generation of T-helper-1-like Treg cells, Nature Commutations, DOI: 10.1038/ncomms13559 (2016).
4. M.H.Feng, B.Q.Tang, **H.X.Xu***, X.F. Jiang*, Collective Synthesis of Phenanthridinone through C-H Activation Involving a Pd-Catalyzed Aryne Multicomponent Reaction, Organic Letters, 18(17):4352-5(2016).
5. L.Zhang, J.L.Feng, S.Y.Kong, M.Wu, Z.C.Xia, B.J.Zhang, W.W.Fu, Y.Z.Lao, H.S.Tan*, **H.X.Xu***; Nujiangexathone A, a novel compound from Garcinia nujiangensis, suppresses cervical cancer growth by targeting hnRNPK, Cancer Letters, 380(2):447-456 (2016).

Five representative publications beyond the recent five-year period *(* Corresponding Author)*

1. B.J.Zhang, W.W.Fu, R.Wu, J.L.Yang, C.Y.Yao, B.X.Yan, H.S.Tan, C.W.Zheng, Z.J. Song*, **H.X.Xu** *, Bioactive scalemic caged xanthones from the leaves of Garcinia bracteata, Bioorganic Chemistry, doi: https://doi.org/10.1016/j.bioorg.2018.10.041 (2018)
2. M.Wu, Y.Z.Lao, H.S.Tan, G.Lu, Y.Ren, Z.Q.Zheng, J.Yi, W.W.Fu, H.M.Shen*, **H .X . Xu** *, Oblongifolin C suppresses lysosomal function independently of TFEB nuclear translocation, Acta pharmacologica sinica. doi: 10.1038/s41401-018-0167-7. (2018)
3. H.Zhang, J.M.Jiang, D.Zheng, M.Yuan, Z.Y.Wang 2, H.M.Zhang, C.W.Zheng, L.B.Xiao*, **H.X.Xu** *.A multidimensional analytical approach based on time-decoupled online comprehensive two-dimensional liquid chromatography coupled with ion mobility quadrupole time-of-flight mass spectrometry for the analysis of ginsenosides from white and red ginsengs. Journal of Pharmaceutical and Biomedical Analysis, 163:24-33, (2019)
4. L.F.Xu, X.X.Meng, N.H.Xu, W.W.Fu, H.S.Tan, L.Zhang, Q.J.Zhou, J.N.Qian, S.W.Tu, X.T. Li, Y.Z. Lao*, **H.X.Xu** *, Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth, Cell Death & Disease, 9: 262 (2018)
5. Y.Li, Z.C.Xi, X.Q. Chen, S.F. Cai, C. Liang, Z. Wang, Y.Y. Li, H.S. Tan, Y.Z. Lao*, **H .X . Xu*,** Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways, Cell Death Disease, 9(5):538, doi: 10.1038/s41419-018-0574-1. (2018)